CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 442 filers reported holding CRISPR THERAPEUTICS AG in Q2 2022. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $334,862 | -88.0% | 6,200 | -84.9% | 0.04% | -85.8% |
Q1 2024 | $2,794,560 | +174.6% | 41,000 | +126.2% | 0.27% | +145.0% |
Q2 2023 | $1,017,762 | +95.7% | 18,129 | +41.7% | 0.11% | +43.4% |
Q4 2022 | $519,995 | +65.6% | 12,792 | +155.8% | 0.08% | +61.7% |
Q1 2022 | $314,000 | +19.4% | 5,000 | -19.4% | 0.05% | -17.5% |
Q1 2020 | $263,000 | +21.8% | 6,200 | +35.0% | 0.06% | +26.7% |
Q2 2019 | $216,000 | -36.3% | 4,594 | -51.6% | 0.04% | -30.8% |
Q1 2019 | $339,000 | – | 9,500 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |